We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

1,277 hedge funds and large institutions have $81.9B invested in Vertex Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 533 increasing their positions, 459 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 533 | Existing positions reduced: 459

9% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 77

6% more call options, than puts

Call options by funds: $674M | Put options by funds: $633M

1% less funds holding

Funds holding: 1,285 → 1,277 (-8)

0.97% less ownership

Funds ownership: 92.34% → 91.37% (-0.97%)

2% less capital invested

Capital invested by funds: $83.3B → $81.9B (-$1.4B)

6% less funds holding in top 10

Funds holding in top 10: 33 → 31 (-2)

Holders
1,277
Holders Change
-8
Holders Change %
-0.62%
% of All Funds
20.27%
Holding in Top 10
31
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-6.06%
% of All Funds
0.49%
New
84
Increased
533
Reduced
459
Closed
77
Calls
$674M
Puts
$633M
Net Calls
+$40.6M
Net Calls Change
-$35.8M

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$224M
2
First Trust Advisors
First Trust Advisors
Illinois
+$178M
3
Renaissance Technologies
Renaissance Technologies
New York
+$137M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$119M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$109M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$359M
2
Millennium Management
Millennium Management
New York
-$182M
3
VNIM
Vaughan Nelson Investment Management
Texas
-$170M
4
Man Group
Man Group
United Kingdom
-$134M
5
State Street
State Street
Massachusetts
-$102M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
551
Decatur Capital Management
Georgia
$2.08M – – –
PCM
552
Prelude Capital Management
New York
$2.08M -$202K -577 -9%
TMAM
553
Tokio Marine Asset Management
Japan
$2.07M +$258K +739 +14%
NFC
554
Northeast Financial Consultants
Connecticut
$2.06M +$28.3K +81 +1%
TSS
555
Two Sigma Securities
New York
$2.06M +$1.63M +4,647 +361%
LNWWM
556
Laird Norton Wetherby Wealth Management
California
$2.06M +$37.4K +107 +2%
3IP
557
3Chopt Investment Partners
Virginia
$2.06M +$39.2K +112 +2%
RBFC
558
Roman Butler Fullerton & Co
Missouri
$2.04M -$143K -410 -7%
NG
559
NatWest Group
United Kingdom
$2.03M +$44.4K +127 +2%
CIAS
560
Capital Investment Advisory Services
North Carolina
$2.01M +$50.4K +144 +3%
AA
561
AlphaMark Advisors
Kentucky
$2.01M -$185K -528 -8%
TWC
562
TD Waterhouse Canada
Ontario, Canada
$1.99M +$420K +1,202 +28%
FA
563
FDx Advisors
Illinois
$1.99M -$1.1M -3,153 -35%
NSAM
564
North Star Asset Management
Wisconsin
$1.99M – – –
AIMCA
565
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.98M – – –
CIBC Private Wealth Group
566
CIBC Private Wealth Group
Georgia
$1.98M +$1.42M +4,052 +247%
HIS
567
Horizon Investment Services
Indiana
$1.96M -$20.3K -58 -1%
RWA
568
Redhawk Wealth Advisors
Minnesota
$1.96M +$54.9K +157 +3%
DAM
569
Draper Asset Management
New York
$1.93M +$230K +657 +13%
PHIMC
570
Private Harbour Investment Management & Counsel
Ohio
$1.93M -$10.1K -29 -0.5%
HWAM
571
Hennion & Walsh Asset Management
New Jersey
$1.93M +$494K +1,412 +34%
1832 Asset Management
572
1832 Asset Management
Ontario, Canada
$1.92M +$292K +834 +18%
LTAS
573
Linden Thomas Advisory Services
North Carolina
$1.9M -$2.5M -7,135 -57%
BFA
574
Brendel Financial Advisors
New Hampshire
$1.89M +$83.6K +239 +5%
HCA
575
Harbour Capital Advisors
Virginia
$1.89M +$107K +305 +6%
21 22
23
24 25

VRTX Hedge Fund Activity: Q3 2023 in Review

1,277 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2023, worth a combined $81.9B — down 1.7% from $83.3B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new VRTX positions and 77 closed out — a net gain of 7 holders — while 533 added to existing stakes and 459 trimmed.

The largest buyer was Capital World Investors, adding an estimated $224M. The largest seller was Wellington Management Group, cutting an estimated $359M.

  • 1,277 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2023, down from 1,285 in Q2 2023.
  • Funds reported $81.9B of Vertex Pharmaceuticals stock for Q3 2023, down 1.7% quarter-over-quarter.
  • 84 funds opened new Vertex Pharmaceuticals positions in Q3 2023 and 77 closed out, a net change of +7 holders.
  • The largest Vertex Pharmaceuticals buyer in Q3 2023 was Capital World Investors, an estimated $224M added.
  • The largest Vertex Pharmaceuticals seller in Q3 2023 was Wellington Management Group, an estimated $359M sold.

Based on aggregated 13F filings for Q3 2023.